Table 7.

Included studies—nonsurgical treatment of peri-implantitis: adjunctive antiseptic therapy

Publication	Design	Population	Case definition	Period	Test	Control	Mean (SD) outcome
Machtei et al. [23]	Multicentre RCT, parallel	60 patients	PD = 6–10 mm and BOP + radiographic bone loss	6 months	OHI + ultrasonic debridement + matrix containing 2.5-mg CHX chips (i.e. up to 4 per implant site)	OHI + ultrasonic debridement + biodegradable crosslinked gelatin matrix chip	Test
		77 implants			Repeated application at sites with PD ≥6 mm at 2, 4, 6, 8, 12 and 18 weeks	Repeated application at sites with PD ≥6 mm at 2, 4, 6, 8, 12 and 18 weeks	BOP: 100 (0.0) (BL) to 42.5 (50.0) % (6 months, subject level)
							PD: 7.6 (1.1) (0.0) to 5.47 (1.86) mm (6 months, subject level)
							Control
							BOP: 100 (0.0) (BL) to 54.5 (50.5) % (6 months, subject level)
							PD: 7.21 (1.08) (BL) to 5.48 (1.25) mm (6 months, subject level)
							BOP and PD reductions at 6 months not sign. different between groups

BL baseline, BOP bleeding on probing, CHX chlorhexidine digluconate, OHI oral hygiene instructions, PD probing pocket depth, RCT randomized controlled clinical study